<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Success of <z:chebi fb="0" ids="38637">tyrosine kinase inhibitors</z:chebi> (TKIs) in <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:mp ids='MP_0005481'>CML</z:mp>) has given patients hope for a long disease-free-survival </plain></SENT>
<SENT sid="1" pm="."><plain>A longer survival raises the question of late effects, including development of another <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Records of 1445 patients with <z:mp ids='MP_0005481'>CML</z:mp>/myeloproliferative <z:hpo ids='HP_0002664'>neoplasm</z:hpo> or other <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e> treated with TKIs were reviewed to investigate frequency and characteristics of <z:e sem="disease" ids="C0085183" disease_type="Neoplastic Process" abbrv="">second malignancies</z:e> (other than <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo>, <z:hpo ids='HP_0011009'>acute</z:hpo> lymphocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo>, or <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>) </plain></SENT>
<SENT sid="3" pm="."><plain>The number of <z:e sem="disease" ids="C0751623" disease_type="Neoplastic Process" abbrv="">second cancers</z:e> was compared with the number expected from the Surveillance, Epidemiology, and End Results database </plain></SENT>
<SENT sid="4" pm="."><plain>After a median follow-up of 107 months (range, 13-362 months) after <z:mp ids='MP_0005481'>CML</z:mp>/myeloproliferative <z:hpo ids='HP_0002664'>neoplasm</z:hpo> diagnosis, 66 patients (4.6%) developed 80 second <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e>, including skin (31%), prostate (15%), <z:hpo ids='HP_0002861'>melanoma</z:hpo> (13%), digestive system (10%), kidney (4%), thyroid (4%), breast (3%), <z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo> (3%), hepatobiliary (3%), and other <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> (14%) </plain></SENT>
<SENT sid="5" pm="."><plain>Excluding <z:e sem="disease" ids="C0699893" disease_type="Neoplastic Process" abbrv="">nonmelanoma skin cancers</z:e>, 55 second <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> were seen in 51 (3.5%) of <z:hpo ids='HP_0000001'>all</z:hpo> patients treated </plain></SENT>
<SENT sid="6" pm="."><plain>The risk of <z:e sem="disease" ids="C0751623" disease_type="Neoplastic Process" abbrv="">second cancer</z:e> was lower than expected (observed-to-expected ratio, 0.6; 95% confidence interval, 0.44-0.81) </plain></SENT>
<SENT sid="7" pm="."><plain><z:e sem="disease" ids="C0751623" disease_type="Neoplastic Process" abbrv="">Second cancers</z:e> occur in a small percentage of patients receiving therapy with TKIs for <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e>, mostly <z:mp ids='MP_0005481'>CML</z:mp> </plain></SENT>
<SENT sid="8" pm="."><plain>No evidence at the moment suggests that exposure to TKIs increases the risk of developing <z:e sem="disease" ids="C0751623" disease_type="Neoplastic Process" abbrv="">second cancers</z:e> </plain></SENT>
</text></document>